‘Pent-up demand’ for FDA-approved cannabis drug boosts UK maker

Don’t believe the hype. Get realistic market forecasts, state by state insights and benchmarks for all cannabis sectors. Preorder the 2023 Factbook here. 

Strong patient interest in the only federally approved CBD product in the United States helped drugmaker GW Pharmaceuticals record $72 million in revenue last quarter.

Epidiolex, which is made by London’s GW Pharma (Nasdaq: GWPH), is a seizure control drug approved by the U.S. Food and Drug Administration.

It has seen brisk sales and new patient enrollments since the drug’s launch last November.

The company said Epidiolex sales were $68.4 million for the quarter that ended in June.

It also reported Epidiolex has been used by more than 12,000 patients coming from about 2,500 physicians since its launch.

Company executives say Epidiolex is benefiting from “pent-up demand” for a regulated CBD treatment.

For more about where the company thinks pharmaceutical CBD is headed, click here.